麻豆传媒

My clinical and research interests are in the diagnosis and treatment of breast cancer. I am interested in clinical trial development and investigation of novel or new treatment options for patients with breast cancer. I am also interested in improving access to clinical trials to diverse patient populations. 






Education

Residency, INTERNAL MEDICINE - Boston University, School of Medicine
M.D. 2016 - Boston University, School of Medicine




 
I am interested in clinical research to develop novel therapeutic agents to further advance the field of breast oncology. My goal is to further the development of novel therapeutic agents through clinical trial development and better access to clinical trials for all patients. I've been involved in research projects to improve the care oncology patients receive as well as clinical research to investigate the genomic differences within breast cancer and how we can find targets to continue to improve personalized breast cancer treatment.





 

Dr. Rachel Freedman is a medical oncologist and clinical researcher at DFCI in the Breast Oncology Program.  In addition to seeing patients with breast cancer, her research focuses on improving the care of vulnerable patient populations who are under-represented in clinical trials and who are at risk for worse breast cancer outcomes, including older women and those who face challenges in access to care.  In addition, she is interested in novel therapeutics, serving as the Principal Investigator for several clinical trials.  She is also the founder and Director of the Program for Older Adults with Breast Cancer at DFCI.  Dr. Freedman joined the faculty at DFCI in 2009.  She studied at Georgetown University School of Medicine and obtained her master's in public health at the Harvard University T.H. Chan School of Public Health.  Her research has been funded by Susan G Komen, ACS, NCI, Gateway for Cancer Research, METAvivor, and the Alliance for Clinical Trials Foundation.

Dr. Garrido-Castro is a medical oncologist specialized in breast cancer at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School.  Since joining the Breast Oncology Center at Dana-Farber in 2016, Dr. Garrido-Castro has established an active clinical practice and research efforts focused on the development of novel therapies to improve outcomes in patients with breast cancer.  Dr. Garrido-Castro is Co-Director of the Triple-Negative Breast Cancer (TNBC) Working Group at Dana-Farber and leads clinical trials studying immunotherapy and targeted therapy approaches for patients with breast cancer.

Dr. Tolaney received her undergraduate degree from Princeton University in 1998 and her medical degree from UC San Francisco in 2002. She subsequently completed her residency in Internal Medicine at Johns Hopkins University, and fellowships in hematology and medical oncology at Dana-Farber Cancer Institute. She obtained a Masters in Public Health from the Harvard School of Public Health in 2007. In 2008, she joined the staff of Dana-Farber Cancer Institute and Brigham and Women's Hospital, where she serves as Chief of the Division of Breast Oncology.  She is a breast medical oncologist whose research focuses on the development of novel therapies in the treatment of breast cancer.  She has been instrumental in developing several treatment approaches for breast cancer, including approaches focused on tailoring therapy for early stage HER2+ disease, use of cdk 4/6 inhibitors, antibody drug conjugates, and immunotherapy.